on Pharnext (EPA:ALPHA)
Pharnext begins liquidation proceedings
Paris, August 27, 2024 – Pharnext SCA, a biopharmaceutical company specializing in neurodegenerative diseases, announced the opening of its compulsory liquidation by the Paris Commercial Court on August 22.
Pharnext had previously informed that it could no longer finance its activity beyond the conciliation procedure closed on July 15, 2024. The company had therefore requested this liquidation itself, a request accepted by the court.
SELAFA MJA, represented by Maître Lucile Jouve, will be responsible for the liquidation. The listing of Pharnext shares is suspended as of August 27, 2024.
Creditors have priority over Pharnext's assets; shareholders should therefore not receive any payment when the assets are sold.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pharnext news